e1. Haugen M, Frederiksen JL, Degn M. B cell follicle-like structures in multiple sclerosis-with focus on the role of B cell activating factor. J Neuroimmunol. 2014;273:1–7.

e2. Magliozzi R, Serafini B, Rosicarelli B, et al. B-cell enrichment and Epstein-Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis. J Neuropathol Exp Neurol. 2013;72:29–41.

e3. Lehmann-Horn K, Kinzel S, Feldmann L, et al. Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity. Ann Clin Transl Neurol. 2014;1:490–496.

e4. Palanichamy A, Apeltsin L, Kuo TC, et al. Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis. Sci Transl Med. 2014;6:248ra106.

e5. Mathias A, Perriard G, Canales M, et al. Increased ex vivo antigen presentation profile of B cells in multiple sclerosis. Mult Scler. 2017;23:802–809.

e6. Michel L, Touil H, Pikor NB, Gommerman JL, Prat A, Bar-Or A. B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized Inflammation. Front Immunol. 2015;6:636.

e7. Eggers EL, Michel BA, Wu H, et al. Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients. JCI Insight. 2017;2:e92724.

e8. Lossius A, Tomescu-Baciu A, Holmøy T, et al. Selective intrathecal enrichment of G1m1-positive B cells in multiple sclerosis. Ann Clin Transl Neurol. 2017;4:756–761.

e9. Stein J, Xu Q, Jackson KC, et al. Intrathecal B Cells in MS Have Significantly Greater Lymphangiogenic Potential Compared to B Cells Derived From Non-MS Subjects. Front Neurol. 2018;9:554.

e10. Stern JNH, Yaari G, Vander Heiden JA, et al. B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes. Sci Transl Med. 2014;6:248ra107.

e11. Lisak RP, Nedelkoska L, Benjamins JA, et al. B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro. J Neuroimmunol. 2017;309:88–99.

e12. Benjamins JA, Nedelkoska L, Touil H, et al. Exosome-enriched fractions from MS B cells induce oligodendrocyte death. Neurol Neuroimmunol Neuroinflamm. 2019;6:e550.

e13. Rivas JR, Ireland SJ, Chkheidze R, et al. Peripheral VH4+ plasmablasts demonstrate autoreactive B cell expansion toward brain antigens in early multiple sclerosis patients. Acta Neuropathol. 2017;133:43–60.

e14. Guerrier T, Labalette M, Launay D, et al. Proinflammatory B-cell profile in the early phases of MS predicts an active disease. Neurol Neuroimmunol Neuroinflamm. 2018;5:e431.

e15. Shen P, Fillatreau S. Antibody-independent functions of B cells: a focus on cytokines. Nat Rev Immunol. 2015;15:441–451.

e16. Büdingen H-C, Palanichamy A, Lehmann-Horn K, Michel BA, Zamvil SS. Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets. Eur Neurol. 2015;73:238–246.

e17. Rijvers L, Melief M-J, van der Vuurst de Vries RM, et al. The macrophage migration inhibitory factor pathway in human B cells is tightly controlled and dysregulated in multiple sclerosis. Eur J Immunol. 2018;48:1861–1871.

e18. Molnarfi N, Schulze-Topphoff U, Weber MS, et al. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med. 2013;210:2921–2937.

e19. Barr TA, Shen P, Brown S, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med. 2012;209:1001–1010.

e20. Li R, Rezk A, Miyazaki Y, et al. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med. 2015;7:310ra166.

e21. Wurth S, Kuenz B, Bsteh G, et al. Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study. PLoS ONE. 2017;12:e0182462.

e22. Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394:1352–1363.

e23. Halliley JL, Tipton CM, Liesveld J, et al. Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow. Immunity. 2015;43:132–145.

e24. Mei HE, Wirries I, Frölich D, et al. A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow. Blood. 2015;125:1739–1748.

e25. Schuh E, Berer K, Mulazzani M, et al. Features of Human CD3+CD20+ T Cells. J Immunol. 2016;197:1111–1117.

e26. Jelcic I, Al Nimer F, Wang J, et al. Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis. Cell. 2018;175:85-100.e23.

e27. Fraussen J, Claes N, van Wijmeersch B, et al. B cells of multiple sclerosis patients induce autoreactive proinflammatory T cell responses. Clin Immunol. 2016;173:124–132.

e28. Ireland SJ, Guzman AA, Frohman EM, Monson NL. B cells from relapsing remitting multiple sclerosis patients support neuro-antigen-specific Th17 responses. J Neuroimmunol. 2016;291:46–53.

e29. Machado-Santos J, Saji E, Tröscher AR, et al. The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells. Brain. 2018;141:2066–2082.

e30. Knier B, Hiltensperger M, Sie C, et al. Myeloid-derived suppressor cells control B cell accumulation in the central nervous system during autoimmunity. Nat Immunol. 2018;19:1341–1351.

e31. Hohlfeld R, Dornmair K, Meinl E, Wekerle H. The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research. The Lancet Neurology. 2016;15:317–331.

e32. Gingele S, Jacobus TL, Konen FF, et al. Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis Patients. Cells. 2018;8.

e33. Sabatino JJ, Wilson MR, Calabresi PA, Hauser SL, Schneck JP, Zamvil SS. Anti-CD20 therapy depletes activated myelin-specific CD8+ T cells in multiple sclerosis. Proc Natl Acad Sci U S A. 2019;116:25800–25807.

e34. Bar-Or A, Calabresi PAJ, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial. Ann Neurol. 2008;63:395–400.

e35. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676–688.

e36. Hartung H-P, Aktas O. Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope. Ann Neurol. 2009;66:429–432.

e37. Alcalá C, Gascón F, Pérez-Miralles F, et al. Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study. J Neurol. 2018;265:1690–1697.

e38. Durozard P, Maarouf A, Boutiere C, et al. Efficacy of rituximab in refractory RRMS. Mult Scler. 2018:1352458518772748.

e39. Naegelin Y, Naegelin P, Felten S von, et al. Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis. JAMA Neurol. 2019:274-281.

e40. Turner B, Cree BAC, Kappos L, et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol. 2019:1182-1193.

e41. D'Amico E, Zanghì A, Chisari CG, et al. Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience. Mult Scler Relat Disord. 2019;27:324–326.

e42. Zecca C, Bovis F, Novi G, et al. Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience. Mult Scler. 2019:1352458519872889.

e43. Salzer J, Svenningsson R, Alping P, et al. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. Neurology. 2016;87:2074–2081.

e44. Spelman T, Frisell T, Piehl F, Hillert J. Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Mult Scler. 2018;24:1087–1095.

e45. Granqvist M, Boremalm M, Poorghobad A, et al. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis. JAMA Neurol. 2018;75:320–327.

e46. Disanto G, Ripellino P, Riccitelli GC, et al. De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis. Mult Scler. 2020:1352458520952036.

e47. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378:1779–1787.

e48. Mulero P, Midaglia L, Montalban X. Ocrelizumab: A new milestone in multiple sclerosis therapy. Ther Adv Neurol Disord. 2018;11:1756286418773025.

e49. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017;376:221–234.

e50. Hauser SL, Kappos L, Arnold DL, et al. Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology. 2020:in press.

e51. Hauser S, Bar-Or A, Cohen J, et al. Ofatumumab versus teriflunomide in relapsing multiple sclerosis: analysis of no evidence of disease activity (NEDA-3) from ASCLEPIOS I and II trials. Eur J Neurol. 2020;27:1268–1307.

e52. Fox EJ, Markowitz C, Applebee A, et al. Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial. Mult Scler. 2018;24:1862–1870.

e53. Ellwardt E, Rolfes L, Klein J, et al. Ocrelizumab initiation in patients with MS: A multicenter observational study. Neurol Neuroimmunol Neuroinflamm. 2020;7.

e54. Stahnke AM, Holt KM. Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis. Ann Pharmacother. 2018;52:473–483.

e55. Mayer L, Kappos L, Racke MK, et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord. 2019:236–243.

e56. Signoriello E, Bonavita S, Di Pietro A, et al. BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab. Mult Scler Relat Disord. 2020;43:102186.

e57. Nosadini M, Alper G, Riney CJ, et al. Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2016;3:e188.

e58. Quan C, ZhangBao J, Lu J, et al. The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy. J Neuroimmunol. 2015;282:45–53.

e59. European Medical Agency (EMA). Ocrelizumab:product information.www.ema.europa.eu/en/medicines/human/EPAR/ocrevus

e60. Havrdová E, Arnold DL, Bar-Or A, et al. No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Mult Scler J Exp Transl Clin. 2018;4:2055217318760642.

e61. McCool R, Wilson K, Arber M, et al. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis. Mult Scler Relat Disord. 2019;29:55–61.

e62. Wolinsky JS, Montalban X, Hauser SL, et al. Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Ann Neurol. 2018:527–536.

e63. Barkhof F, Kappos L, Wolinsky JS, et al. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology. 2019:e1778-e1786.

e64. Wolinsky JS, Engmann NJ, Pei J, Pradhan A, Markowitz C, Fox EJ. An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability. Mult Scler J Exp Transl Clin. 2020;6:2055217320911939.

e65. MacMillan EL, Schubert JJ, Vavasour IM, et al. Magnetic resonance spectroscopy evidence for declining gliosis in MS patients treated with ocrelizumab versus interferon beta-1a. Mult Scler J Exp Transl Clin. 2019;5:2055217319879952.

e66. Elliott C, Belachew S, Wolinsky JS, et al. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain. 2019;142:2787–2799.

e67. Hartung H-P, ENSEMBLE steering committee members and study investigators. Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MS. Neurol Neuroimmunol Neuroinflamm. 2020;7:e807.

e68. Bar-Or A, Calkwood JC, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology. 2020:in press.

e69. Cree BA. Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Commentary. Mult Scler. 2018;24:1161–1162.

e70. Piehl F, Hillert J. Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Yes. Mult Scler. 2018;24:1157–1159.

e71. Wallin MT. Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - No. Mult Scler. 2018;24:1159–1161.

e72. Graf J, Aktas O, Rejdak K, Hartung H-P. Monoclonal Antibodies for Multiple Sclerosis: An Update. BioDrugs. 2019;33:61–78.

e73. Ineichen BV, Moridi T, Granberg T, Piehl F. Rituximab treatment for multiple sclerosis. Mult Scler. 2019:1352458519858604.

e74. Sorensen PS, Lisby S, Grove R, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology. 2014;82:573–581.

e75. Hauser SL , Bar-Or A, Cohen J, Comi G., Correale J, Coyle PK, Cross AH, de Seze J, Montalban X, Selmaj K, Wiendl H, Goodyear A, Häring DA, Kerloeguen C, Tomic D, Willi R, Ramanathan K, Merschhemke M, Kappos L. Efficacy and safety of ofatumumab versus teriflunomide in relapsing multiple sclerosis: results of the phase 3 ASCLEPIOS I and II trials [online]. Available at: onlinelibrary.ectrims-congress.eu/ectrims/2019/stockholm/279581/stephen.hauser.efficacy.and.safety.of.ofatumumab.versus.teriflunomide.in.html.

e76. Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383:546–557.

e77. Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM, Ashkenazi A. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Current Biolo. 2000;10:785–788.

e78. Seyler TM, Park YW, Takemura S, et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest. 2005;115:3083–3092.

e79. Wang X, Xiao H, Wei Y, et al. Blockade of B-cell activating factor with TACI-IgG effectively reduced Th1 and Th17 cells but not memory T cells in experimental allergic encephalomyelitis mice. Cent Eur J Immunol. 2015;40:142–148.

e80. Hartung H-P, Kieseier BC. Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord. 2010;3:205–216.

e81. Kappos L, Hartung H-P, Freedman MS, et al. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol. 2014;13:353–363.

e82. Lühder F, Gold R. Trial and error in clinical studies: lessons from ATAMS. The Lancet Neurology. 2014;13:340–341.

e83. Thi Cuc B, Pohar J, Fillatreau S. Understanding regulatory B cells in autoimmune diseases: the case of multiple sclerosis. Curr Opin Immunol. 2019;61:26–32.

e84. Chang H-D, Tokoyoda K, Hoyer B, et al. Pathogenic memory plasma cells in autoimmunity. Curr Opin Immunol. 2019;61:86–91.

e85. Baker D, Pryce G, James LK, Schmierer K, Giovannoni G. Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis. Eur J Neurol. 2020;27:221–228.

e86. Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K. Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine. 2017;16:41–50.

e87. Kaegi C, Steiner UC, Wuest B, Crowley C, Boyman O. Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders. Front Immunol. 2020;11:433.

e88. Vigolo M, Chambers MG, Willen L, et al. A loop region of BAFF controls B cell survival and regulates recognition by different inhibitors. Nat Commun. 2018;9:1199.

e89. Kargbo RB. Bruton's Tyrosine Kinase Inhibitors for the Treatment of Autoimmune Diseases and Cancers. ACS Med Chem Lett. 2017;8:911–913.

e90. Burger JA. Bruton Tyrosine Kinase Inhibitors: Present and Future. Cancer J. 2019;25:386–393.

e91. Wu J, Zhang M, Liu D. Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside. Oncotarget. 2017;8:7201–7207.

e92. Wu J, Liu C, Tsui ST, Liu D. Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol. 2016;9:80.

e93. Haselmayer P, Camps M, Liu-Bujalski L, et al. Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models. J Immunol. 2019;202:2888–2906.

e94. Liang C, Tian D, Ren X, et al. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review. Eur J Med Chem. 2018;151:315–326.

e95. Kim H-O. Development of BTK inhibitors for the treatment of B-cell malignancies. Arch Pharm Res. 2019;42:171–181.

e96. Caldwell RD, Qiu H, Askew BC, et al. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. J Med Chem. 2019;62:7643–7655.

e97. Watterson SH, Liu Q, Beaudoin Bertrand M, et al. Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK). J Med Chem. 2019;62:3228–3250.

e98. Becker A, Martin EC, Mitchell DY, et al. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers. Clin Transl Sci. 2020;13:325–336.

e99. Catlett IM, Nowak M, Kundu S, et al. Safety, Pharmacokinetics and Pharmacodynamics of Branebrutinib (BMS-986195), a Covalent, Irreversible Inhibitor of Bruton's Tyrosine Kinase: Randomised Phase I, Placebo-Controlled Trial in Healthy Participants. Br J Clin Pharmacol. 2020 Mar 21.:doi: 10.1111/bcp.14290.

e100. Mullard A. BTK inhibitors get a boost. Nat Rev Drug Discov. 2017;16:818.

e101. Rogers A, Woyach JA. BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL. Ther Adv Hematol. 2020;11:2040620720912990.

e102. Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton's tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17:57.

e103. Pal Singh S, Dammeijer F, Hendriks RW. Correction to: Role of Bruton's tyrosine kinase in B cells and malignancies. Mol Cancer. 2019;18:79.

e104. Sanofi. Sanofi brain-penetrant BTK inhibitor meets primary endpoint of Phase 2 trial in relapsing multiple sclerosis [online]. Available at: www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/media-room/press-releases/2020/2020-02-06-07-00-00-1980729-en.pdf.

e105. Crawford JJ, Johnson AR, Misner DL, et al. Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. J Med Chem. 2018;61:2227–2245.

e106. Torke S, Pretzsch R, Häusler D, et al. Inhibition of Bruton`s tyrosine kinase interferes with pathogenic B cell development in inflammatory CNS demyelinating disease. Acta Neuropathol. 2020 Aug 6. doi: 10.1007/s00401-020-02204-z